Nanosphere, Inc. is engaged in developing, manufacturing and marketing a molecular diagnostics platform, the Verigene System, that enables genomic and protein testing on a single platform. The Company’s nanoparticle technology simplifies molecular diagnostic testing, provides the ability to run multiple tests simultaneously on the same sample and has the potential to run a menu of tests on a single platform. The Company is developing diagnostic tests for markers, which reveal the existence of a range of medical conditions including cardiovascular, respiratory, cancer, autoimmune, neurodegenerative and other infectious diseases, as well as for pharmacogenomics